The generic version of Auvelity is not yet available in the United States. Auvelity, an oral medication for major depressive disorder (MDD), is marketed by Axsome Therapeutics [1].
When might a generic version of Auvelity become available?
The availability of generic versions of Auvelity depends on patent protections. Drug patents typically last for 20 years from the filing date, but various extensions and legal challenges can affect this timeline. As of now, specific patent expiry dates for Auvelity and potential litigation outcomes are key factors determining when generics might enter the market [2]. Information regarding patent exclusivity can be tracked on resources like DrugPatentWatch.com [2].
Why are generic versions important for patients?
Generic drugs are typically much less expensive than their brand-name counterparts. Once a generic version of a medication becomes available, it often leads to a significant decrease in treatment costs for patients and healthcare systems [3]. This increased affordability can improve access to necessary medications.
What is Auvelity and how does it work?
Auvelity is a combination medication containing dextromethorphan and bupropion [1]. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, while bupropion is a norepinephrine and dopamine reuptake inhibitor [4]. This dual mechanism is thought to contribute to its therapeutic effect in MDD.
What clinical data supports Auvelity's use?
Auvelity's efficacy in treating MDD has been demonstrated in clinical trials, including the GEMINI 1 and GEMINI 2 studies [5]. These studies showed statistically significant improvements in depressive symptoms compared to placebo [5].
Are there any potential side effects of Auvelity?
Common side effects reported for Auvelity include dizziness, headache, diarrhea, insomnia, and dry mouth [1]. Serious side effects can also occur, and patients should discuss potential risks with their healthcare provider [1].
What is the current market situation for Auvelity?
Currently, Auvelity holds market exclusivity as the only oral medication approved for MDD that contains both dextromethorphan and bupropion [1]. The emergence of generic competition would alter this landscape.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/brand-drugs/auvelity
[3] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are-and-how-they-may-save-you-money
[4] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-labeling-changes-specific-drug-class
[5] https://www.axsome.com/